Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sandoz To Acquire Oriel Therapeutics

by Ann M. Thayer
April 26, 2010 | A version of this story appeared in Volume 88, Issue 17

Sandoz, the generic drug arm of Novartis, will purchase privately held Oriel Therapeutics for an undisclosed amount. North Carolina-based Oriel develops generics and drug delivery technologies for inhalable respiratory products. According to figures from metrics firm IMS Health, about half of the drugs in the $32 billion global market for asthma and chronic obstructive pulmonary disease medicines are expected to lose patent protection by the end of 2016. Oriel’s investors might receive additional payments if certain milestones are met.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.